WO1994019376A1 - Polysaccharide derivative and drug carrier - Google Patents
Polysaccharide derivative and drug carrier Download PDFInfo
- Publication number
- WO1994019376A1 WO1994019376A1 PCT/JP1994/000322 JP9400322W WO9419376A1 WO 1994019376 A1 WO1994019376 A1 WO 1994019376A1 JP 9400322 W JP9400322 W JP 9400322W WO 9419376 A1 WO9419376 A1 WO 9419376A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- acid
- polysaccharide
- polysaccharide derivative
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
Definitions
- the present invention relates to a drug carrier and a drug complex comprising a novel polysaccharide derivative, and more particularly, to a drug carrier in which a peptide is introduced into a polysaccharide, and further comprising a drug. Regarding the introduced drug complex.
- a water-soluble polymer as a drug carrier has been attempted in the field of pharmaceutical preparations, and many related techniques have been provided. In many cases, it is not possible to use a cardinole, a card, or a card.
- phenolic derivatives such as cellulose has been attempted, and the physicochemical properties of these substances themselves have been used to disperse and sustained release of drugs.
- the drug is integrated with the cellulosic derivative as a carrier by pharmaceutical mixing, but is chemically bonded to the carrier. It is not what we do.
- the present inventors have now studied the possibility of using polysaccharides as drug carriers. As a result, they found that a polysaccharide derivative in which a polypeptide chain was introduced into the polysaccharide had excellent properties as a drug carrier.
- an object of the present invention is to provide a novel drug carrier and a drug conjugate capable of delivering a drug, in which the drug is held to the drug carrier via a chemical bond. ing .
- some or all of the polysaccharides having a carboxyl group contain from 1 to 8 identical or different amino acids in the carboxyl group.
- a part of an amino group or a canolepoxyl group which is not involved in the binding of the peptide chain to the carboxyl group after the introduction of the peptide chain Alternatively, the carboxy group, amino group or hydroxyl group of another compound having a carboxyl group, an amino group or a hydroxyl group, and an acid amide A polysaccharide derivative and a salt thereof which may be bonded or ester-bonded are provided.
- the polysaccharide derivative according to the present invention has high transferability to a tumor, and can efficiently deliver a drug having an adverse effect or a drug having a limited sustained drug effect to the tumor. I can do it.
- the polysaccharide derivative according to the present invention has a property of gradually releasing a drug in the body, it is possible to maintain the drug concentration in the blood for a long time. And can be done.
- a drug carrier and a drug conjugate comprising a polysaccharide derivative are provided.
- the “polysaccharide having a carboxyl group” is essentially a polysaccharide having a carboxyl group in its structure (for example, hyaluronic acid, ⁇ In addition to cutinic acid, anoregic acid, chondroitin, heparin, etc.), polysaccharides that do not inherently have a functional hydroxyl group (for example, , Pullulan, dextran mannan, kitchen, dinulin, renok, xylan, arabin, mannoglucan, chitosan And so on) A part or all of the hydroxyl group hydrogen atoms are substituted with a carboxy c.- 4 alkyl group, or a part or all of the hydroxyl groups are esterified.
- a polybasic acid has been introduced through a thiol bond.
- polysaccharide derivative includes both a case where the compound is a drug carrier and a case where the compound is a drug complex bound to a drug.
- acid amide bond is used to include a urethane bond and an urea bond.
- FIG. 1 shows the carboxymethylpurullan lanthanum salt obtained in Example 1 3′-N- (Gly-Gly-Phe-G1y) -DXR ( 23 Figure 0 "'showing the ultraviolet / visible absorption spectrum (concentration: 300 // g Zral, solvent: water) of 3).
- FIG. 2 shows the carboxymethylpurullan lanthanum salt obtained in Example 1 3′-N- (Gly-Gly-Phe—Gly) -DXR (2
- FIG. 3 is a diagram showing the gel filtration elution pattern (detection: visible absorbance at 4788 nm) of 3).
- FIG. 3 shows the carboxymethylpurullan lanthanum salt obtained in Example 2 3′—N— (Gly-Gly-Phe—Gly) -DXR (2 Figure showing the UV / visible absorption spectrum of 4) (concentration: 300 mg Zm, solvent: water) Is
- FIG. 4 shows the carboxymethyl purrannathium salt-1′-N- (Gly-Gly-Phe—1y) -DXR obtained in Example 2.
- FIG. 4 is a view showing the gel filtration superelution pattern (detection: visible absorbance at 4788 nm) of (24).
- Fig. 5 shows the ultraviolet and visible absorption spectrum of '-N-G1y-DXR (2) obtained from Example 7. (Concentration: 2000 g Zn solvent: water).
- FIG. 6 shows the gel filtration overelution pattern of carboxymethyl pullulannatrium salt obtained from Example 7 —'- N-G1y-DXR (29).
- Figure C ' shows the peaks (detection: visible absorbance at 478 nm).
- FIG. 7 shows the succinyl pullrunnatreme salt N- (Gly-Gly-Phe-G1y) -DXR (42) obtained in Example 15
- the figure shows the absorption spectrum of the ultraviolet and visible regions (concentration: 0 ⁇ gZm1, solvent: water).
- FIG. 8 shows the succinyl-pullanna sodium salt _3'—N- (Gly-Gly-Phe-G1y) -DXR obtained in Example 15
- FIG. 9 showing the gel filtration superelution pattern (detection: visible absorbance at 4778 nm) of (42).
- FIG. 9 is obtained in Example 16. I'm sorry Ultraviolet of 3'-N- (Gly-Gly-Phe-G.1y) -DXR (44) ⁇ Visible absorption peak (concentration: 1) FIG. 1 mg Zml, solvent: water).
- FIG. 10 shows the calcium salt of sodium carboxylmethyltin sodium salt obtained in Example 16 3′-N- (G1y-G1y-Phe-G1
- FIG. 7 is a diagram showing the gel elution pattern (detection: visible absorbance at 4788 nm) of y) -DXR (44).
- FIG. 11 shows the carboxymethyl dextran sodium salt obtained in Example 17 3′-N- (G1y-G1y-Phe - G ly) - DXR (4 6 ultraviolet-visible portion absorption scan Bae click preparative Le (concentration): 4 0 0 ⁇ ⁇ ⁇ 1, solvent: water) Ru Zudea which shows the.
- FIG. 12 shows the carboxymethyl dextran sodium salt obtained in Example 17 3′- ⁇ - (G1y-G1y-Phe -Gly) This is a diagram showing the (46) gel filtration elution pattern (detection: visible absorbance at 4788 nm) of one DXR.
- FIG. 13 shows the carboxymethyl mannoguanole cannatrium salt obtained in Example 18 3′-N- (G1y-Gly-Phe-
- FIG. 4 is a view showing an ultraviolet absorption spectrum spectrum (concentration: 1.12 mg Zm1, solvent water) of Gly) -DXR (48).
- FIG. 14 shows the carboxymethyl mannogonol cannatridium salt obtained in Example 18 3′-N- (G1y-Gly-Phe).
- FIG. 2 is a graph showing the gel elution pattern (detection: visible absorbance at 478 nm) of -Gly) -DXR (48).
- FIG. 15 shows the N-acetyl-de-N-sulfated heparin sodium salt obtained in Example 19
- 3′-N- (G1y-Gly -Phe-Gly) is a diagram showing the UV-visible absorption spectrum of one DXR (50) (concentration: 2557 g Z ml, solvent: water).
- FIG. 16 shows the N—acetyl de-N—sulfated heno obtained in Example 19.
- FIG. 3 is a diagram showing the visible absorbance in nm.
- FIG. 17 is a graph showing the results of comparing the sodium hyaluronate salt obtained in Example 20-3′-N- (Gly-Gly-Phe-Gly) -DXR (5 3) UV / visible absorption spectrum
- FIG. 18 shows the sodium hyaluronate salt obtained in Example 20—3′-N- (Gly-Gly-Phe-Gly) -DXR (5
- FIG. 3 is a diagram showing the gel filtration elution pattern (detection: visible absorbance at 4788 nm) of 3).
- FIG. 19 is a daraf showing the relationship between the dose of the drug conjugate or doxorubicin according to the present invention and the tumor weight.
- FIG. 20 is a graph showing a change in body weight of a normal rat to which the drug conjugate or doxorubicin according to the present invention was administered.
- the polysaccharide derivative according to the present invention includes the ability to have a polysaccharide having a carboxyl group in its structure as a basic skeleton.
- the polysaccharide derivatives according to the present invention include those having, as a basic skeleton, a polysaccharide not having a carboxyl group in its structure.
- the polysaccharide derivative having a polysaccharide having no carboxyl group in its structure as a basic skeleton has hydrogen atoms of a part or all of the hydroxyl groups. Structure in which a hydroxyl group is substituted with a C- 4 alkyl group, or a structure in which a polybasic acid is introduced into a part or all of the hydroxyl groups via an ester bond. And must have a carboxyl group.
- the polysaccharide derivative according to the present invention has a structure in which a peptide chain is introduced into a carboxy group of the polysaccharide.
- Preferable examples of the alkyl group c ⁇ — 4 alkyl group include a carboxyl methyl group, a hydroxyl group, a hydroxyl group, and the like.
- the term “acid” refers to an acid having two or more protons that can be donated in one molecule of the acid, that is, an acid having a basicity of 2 or more.
- Preferred examples of polybasic acids include malonic, succinic, daltanoleic, adipic, maleic, fumaric, and citric acid. Laconic acid, cis aconitic acid, L-asparaginic acid, L-glutamic acid, diglyco-monooleic acid, and the like.
- the degree of introduction of the carboxyalkyl group or polybasic acid depends on the carboxyalkyl group or polybasic acid per sugar residue. It can be described by the "degree of substitution”, which is defined as the number of acids (including the groups into which the peptide chains are further introduced). That is,
- the degree of substitution is hereinafter referred to as "degree of carboxyl methylation" when the carboxyl alkyl group is a carboxyl methyl group, and is referred to as “polybasic methylation degree".
- the acid is succinic acid In some cases, it is called “degree of succinylation”.
- the degree of substitution is 3 when all the hydroxyl groups are substituted, and 0.1 or more is preferable.
- the degree of substitution is 2 when all hydroxyl groups are substituted, and preferably 0.1 or more.
- the degree of substitution is 3 when all hydroxyl groups are substituted, and 0.1 or more is preferable.
- the degree of substitution is 3 when all the hydroxyl groups are replaced, and preferably 0.1 or more o
- the polysaccharide derivative molecule except when the polysaccharide originally has a carboxyl group, at least one carboxyl alkyl group or polybasic group is present in the polysaccharide derivative molecule.
- the acid must be present. Therefore, a compound having a substitution degree of 0 in this sense is excluded from the polysaccharide derivative.
- the peptide chain introduced into the polysaccharide in the present invention has 1 to
- the number of amino acids is more preferably 2 or more in consideration of the drug release characteristics, and is 6 or less in view of the complexity of the synthesis process. Is more preferred, even more preferably 4 or less.
- the type of amino acid is not particularly limited, but according to a preferred embodiment of the present invention, the amino acid is a neutral amino acid.
- the amino acid is a heterogeneous combination.
- examples of such peptides include one Phe—G1y— and a peptide chain that contains this sequence in the chain (here, this peptide).
- P he — G 1 y-and the N-terminus of the peptide chain containing this sequence in the chain has not been introduced into the carboxyl group of the polysaccharide.
- a peptide containing amino acid refers to a peptide chain consisting of only amino acid and a part of the amino acid chain in addition to the amino acid.
- the meaning includes the case where a compound other than an acid is included.
- a dibasic carboxylic acid such as succinic acid may be present in or at the end of the peptide chain.
- the amino acids constituting this peptide chain include ⁇ -amino acids, e-aminocaproic acid, 7-amino drank acid, and the like. It may be a compound similar to amino acid.
- the binding direction of the peptide chain is usually linked to the carboxyl group of the polysaccharide by the N-terminal force and the acid amide bond.
- An amino acid other than an acid (for example, if a lysine is present in the peptide chain, the £ -amino group) can be linked to the carboxyl group of the polysaccharide.
- the binding direction of the peptide chain may be reversed.
- the introduction of the peptide chain into the carboxyl group of the polysaccharide is introduced into the peptide chain, regardless of whether or not the peptide group has any of its powers. It is preferable to determine the degree of introduction appropriately according to the physicochemical and pharmacological properties of the drug.
- the amino acid sequence of this peptide chain is the action of enzymes (for example, proteases, peptidases) in the organs, and can result in the action of a drug or its active molecule.
- the species must be produced quickly and, in some cases, gradually.
- the amic acid may be neutral amic acid, basic amic acid, or acidic amic acid.
- the amino or canolepoxyl group of the peptide is not associated with the carboxyl or amino group of another compound. It may be an acid amide bond or an ester bond with a hydroxyl group or a hydroxyl group.
- Examples of other compounds include compounds that bind to an amino group or a carboxyl group at the terminal of a peptide to protect the peptide.
- the part of the compound that protects the functional group, that is, the protecting group is not limited as long as it is generally used for protecting amino acids.
- protective groups for the amino group include t-butoxycarbonyl group, P-methoxybenzyloxycarbonyl group, and the like.
- a protecting group for a carboxyl group a lower alkoxy group (for example, a t_butyloxy group) or a lower alkylimino group (for example, a methylimino group) Group) Benzoxy group etc. can be mentioned.
- the other compound is a drug having an amino group, a carboxyl group or a hydroxyl group
- the drug is introduced through an acid amide bond or a ester bond.
- Such cases are included in the polysaccharide derivative according to the present invention.
- the polysaccharide derivative according to the present invention can exist as its salt, it is preferable that it is a pharmaceutically acceptable salt in consideration of its use.
- Such salts may include sodium, potassium, calcium, or other alkaline metal or alkaline earth metal salts.
- amino salts such as arginine salts and lysine salts.
- the polysaccharide derivative according to the present invention can be used as a drug carrier for carrying a drug thereon and delivering the drug to a tumor tissue or the like.
- the polysaccharide derivative according to the present invention is expected to release a drug in a living body and not to remain in the body for a long time.
- an antitumor agent or other drug into the peptide chain of the polysaccharide derivative according to the present invention can be accomplished by adding the drug to the amino group or carboxysil of the terminal amino acid of the peptide chain. You can do it using the basics.
- a drug having an amino group can form an acid amide bond with a hydroxyl group of a terminal amino acid.
- a drug having an alcoholic hydroxyl group can form an ester bond with a carboxyl group of a terminal amino acid.
- a drug having a carboxyl group can bind to the amino group of the terminal amino acid.
- Such a drug include doxorubicin, danonorevicin, and mitaminopharmaceuticals having a amino group.
- Meisin :, bleomycin, etc. are listed, and as a drug having an alcoholic hydroxyl group, cyclocytidine, binc Examples include listin, bimblastin, and adrenaline, and the drug having a carboxyl group is Methotre. Examples include xart, bumetanide, flocemid, and ginoprost.
- the rate of introduction of the drug into the polysaccharide derivative is appropriately selected depending on the drug and the kind of the polysaccharide, but is generally as follows.
- polysaccharide When the polysaccharide is pullulan, 0.1 to 30% by weight is preferred, and 1 to 10% by weight is particularly preferred.
- polysaccharide is chitin
- 0.1 to 30% by weight is preferred, and 1 to: L 0% by weight is particularly preferred.
- polysaccharide is dextran
- 0.1 to 30% by weight is preferred, and 1 to: L 0% by weight is particularly preferred.
- polysaccharide is mannoglucan
- 0.1 to 30% by weight is preferred, and 1 to 10% by weight is particularly preferred.
- polysaccharide is N-acetyl de-N-sulfated heparin
- 0.1 to 30% by weight is preferable, and 1 to: L 0% by weight is particularly preferable.
- a drug complex into which a drug has been introduced can also exist as a salt thereof.
- suitable salts include alkali metal or alkaline earth metal salts, such as sodium, potassium, and canoledium salts, and alkaline earth metal salts.
- Amino acid salts such as luginine salt and lysine salt can be mentioned.
- polysaccharides are pullulan, chitin, dextran, mannoglucan, N—acetyl-substituted N—heparin sulfate, and hydranolic acid.
- pullulan chitin
- dextran dextran
- mannoglucan N—acetyl-substituted N—heparin sulfate
- hydranolic acid hydranolic acid
- a polysaccharide derivative in which the polysaccharide is pullulan contains a repeating unit represented by the following formula (I): The thing is.
- R 1 - 9 are the same or is rather good even if Tsu Do different,, respectively Re its hydrogen atom, group - (CH 2) m - CO - X, group one CO - (CH ) N — CO — X or
- X represents a hydrogen atom or a peptide moiety containing 1 to 8 identical or different amino acids, and represents the carboxy group of the peptide chain.
- Some or all of the amino groups or amino groups that are not involved in binding to the boxinole group may be a carboxyl group, an amino group, or the like.
- the compound may have an acid amide bond or an ester bond with the carboxyl group, amino group or hydroxyl group of another compound having a hydroxyl group.
- the molecular weight of the above-mentioned pullulan derivative is 2 ⁇ 10 ′′ to 1 ⁇ 10 in the pullulan portion. ⁇ to be of Chikarakuyoshimi or tooth rather, IX 1 0 4 ⁇ 2 x 1 0 down the well of the Ri good or was not good.
- the pullulan derivative it is preferable that 0.001 to 3.0 peptide chains are introduced per sugar residue, more preferably.
- the range is 0.01 to 0.1.
- a polysaccharide derivative in which the polysaccharide is chitin may contain a repeating unit represented by the following formula (H).
- R 1 one 4 represents the same or is rather good even if Tsu different, even the same content group as defined in each formula (I))
- the molecular weight of the chitin derivative have you the key switch down part of its in 2 X 1 0 3 ⁇ ⁇ ⁇ ⁇ ⁇ 6 of rather also preferred force, 1 x 1 0 4 ⁇ 2 X 1 0 5 to be Is more preferred.
- the chitin derivative preferably has a peptide chain of 0.01 to 2.0 per sugar residue, more preferably ⁇ .01 to 0.1.
- a polysaccharide derivative in which the polysaccharide is dextran (hereinafter sometimes referred to as a “dextran derivative”) is a repeating unit represented by the following formula (H i) , which contains.
- R 1 - 6 represents the same or is rather good even though Tsu Do different, its Re also of the same contents of the groups are defined in the Zoreshiki (I))
- mannoglucan derivative In the dextran derivative, it is preferable that a peptide chain of 0.01 to 3. ⁇ is introduced per sugar residue, and more preferable. It is in the range of 0.01 to 0.1.
- a polysaccharide derivative in which the polysaccharide is mannoglucan (hereinafter sometimes referred to as “mannoglucan derivative”) is a repetitive compound represented by the following formula (IV): A unit containing a unit.
- R 1 - are the same or is rather good even though Tsu Do different, Su Re is also of the same contents of the groups are defined in the Zoreshiki (I) and Table, R 1 0 ⁇ may be the same or different, but each may be R ⁇
- the molecular weight of the above mannoglucan derivative is 2 ⁇ 10 3 or more in the mannoglucan part: LX 10.
- the preferred units are 1 ⁇ 10 4 to 2 ⁇ 10 5 , and the preferred units are more preferred than the manganoglucan derivatives.
- the structure of each saccharide unit falls within any of the ranges of the above general formulas (I) to (I)
- the structure of the adjacent saccharide unit is the same.
- the introduction positions of the carboxylalkyl group or the polybasic acid may be the same or different.
- a polysaccharide derivative whose polysaccharide is N-acetyl-de-N-sulfated heparin (hereinafter sometimes referred to as “heparin derivative”) is represented by the following formula (V). The one that contains the repeating unit represented.
- X represents a peptide chain containing 1 to 8 identical or different amino acids, and the peptide chain is subjected to N-acetyl-de-N-sulfation.
- Some or all of the amino or canolepoxyl groups that are not involved in binding to parin have a carboxyl, amino or hydroxyl group.
- the carboxyl group, the amino group or the hydroxyl group of the other compound, and the acid amino group. May be bonded or ester-bonded.
- the molecular weight of the above heparin derivative is determined by its N-acetyl-de-N-sulfated derivative. Li down part to your stomach of even the 2 X 1 0 3 ⁇ 6 X 1 0 4 is good or tooth rather, 1 X 1 ⁇ 4 ⁇ 6 X 1 0 4 of also of by Ri good or to have Chikaraku.
- a peptide chain of about 0.1 to 2.0 is introduced, and more preferably, a repeating unit. 0 1 to 0,1.
- a polysaccharide derivative in which the polysaccharide is hyaluronic acid (hereinafter sometimes referred to as “hyaluronic acid derivative”) is a repeating unit represented by the following formula (VI): , Which contains.
- the molecular weight of the above hyaluronic acid derivative is preferably 2 ⁇ 10 3 to 6 ⁇ 10 6 in the hyaluronic acid portion, and 1 ⁇ 10 4 ⁇ 2 X 1 0 5 to be of force by Ri good or was not.
- a peptide chain of 0.001 to 0.1 per repeating unit is introduced.
- a polysaccharide modified with a carboxylalkyl group can be obtained by substituting a hydrogen atom of a hydroxyl group of the polysaccharide with a carboxylalkyl group. Specifically, for example, the polysaccharide is converted into a solvent that does not participate in the carboxylalkylation reaction (for example,
- Polysaccharides modified with polybasic acids can be obtained by introducing polybasic acids into the hydroxyl groups of polysaccharides.
- the reaction do not want to participate in a solvent (eg, H 2 0, N, N - di main Chi Honoré e Honoré arm a mi de, etc. di main Chi le sulfo key sheet de), at ⁇ Noreka Li (eg For example, when water is used as a solvent, sodium bicarbonate, carbonated lime, sodium hydroxide, ammonia water, etc.
- dimethyl honole amide or dimethyl sulfoxide, pyridin, triethylamine or acetic acid Under ice-cooling to a temperature of 80 ° C. What can be obtained by reacting for several minutes to several days is obtained. In the case of, the "degree of substitution" can be adjusted by changing the temperature and the amount of addition of the pressure.
- the polysaccharide derivative according to the present invention can be obtained by introducing a peptide into a carboxyl group of the polysaccharide.
- a peptide into a carboxyl group of the polysaccharide.
- the carboxyl group of the polysaccharide and the peptide chain are examples of the polysaccharide.
- the polysaccharide and the C-terminally protected peptide chain are reacted in the presence of a solvent that does not participate in the reaction. It can be obtained by reacting at a temperature of 0 for several hours to several hours.
- a suitable condensing agent for example, N, N'-disc mouth hexyl force rubodiimide, hydrochloric acid 1-ethyl chloride 3 —
- the degree of introduction of the peptide chain into the polysaccharide can be adjusted according to the amount of the peptide to be added. Therefore, if it is desired to introduce a peptide group to all carboxyl groups, it is preferable to react an excess amount of the peptide.
- the drug conjugate has a drug in the peptide of the polysaccharide derivative obtained as described above, and each of the peptide and the drug. It can be obtained by introducing via a bond of a functional group.
- the introduction of a drug into the peptide chain involves reacting the carboxyl or amino group of the peptide chain with a functional group or an activated substituent of the drug. You can do this by letting them do it.
- a drug having an amino group at the C-terminus is introduced through an acid amide bond.
- This reaction may optionally involve the conversion of a drug, such as an N-hydroxysuccinate imidester, to an active ester such as a drug and an acid amide. It can be carried out by reacting under the conditions for bond formation.
- introduction into the C-terminus can be carried out via an ester bond with a drug having an alcoholic hydroxyl group at the C-terminus.
- a drug having a carboxyl group at this N-terminus can be introduced via an acid amide bond.
- the polysaccharide derivative according to the present invention may be obtained in the order of obtaining a drug into which a peptide chain has been introduced first and introducing it into the polysaccharide.
- the introduction of a drug into a peptide peptide can be appropriately performed according to the nature of the functional group to be used, similarly to the introduction of a drug into a polysaccharide derivative described above. You.
- the reaction of the peptide chain It is preferred that the N-terminus or C-terminus not involved in the reaction be protected with a protecting group.
- polysaccharide in which some of the hydroxyl groups have been etherified with, for example, polyethylene glycol. It is also possible to decompose the polysaccharide into a substance having an arbitrary molecular weight by using an enzyme and use it.
- the degree of carboxymethylation or the degree of succinylation of the polysaccharide derivative was determined by phenol titration.
- the amount (% by weight) of the drug introduced was determined by absorbance analysis (around 478 nm) using the characteristic absorption of the drug.
- the gel filtration method was carried out under the following conditions (force column: 81 (861 64000? ⁇ ⁇ , Eluent: 0.1 MNaCl, flow rate: 0.8 ml /). min, column temperature: 40 ° C, sample injection amount: about 50 ⁇ g).
- DXR Doxonorubicin
- DNR Downolubicin
- Trt Triphenylmethyl group (tritinol group).
- Dialysis was performed for 2 days at 4 C using purified water as an external solution using a cut-off of 12,200 to 14,00,000 (manufactured by Spectrum). The dialysate was removed and freeze-dried to obtain the title compound (2) (8.7 g). The degree of carboxyl methylation per sugar residue of this substance was 0.6.
- Purulan (7) (0.5 g, weight average molecular weight: about 23,000) (manufactured by Hayashibara Biochemical Laboratory Co., Ltd.) was added to 6N sodium hydroxide solution (7B1 ⁇ ). Dissolved. Then, acetic acid (1.5 g) was added thereto, and the mixture was stirred at 70 ° C for 2 hours. After the reaction, methanol (10 Oral) was added, and the mixture was centrifuged, and the deposited precipitate was dried under reduced pressure. After repeating the same operation one more time, it was dissolved in purified water (10 ml), and the solution was dialyzed (molecular weight cut-off 1, 000, manufactured by Spectra).
- N a — T rt -G ly -G ly — P he -G ly (9) (475 mg> 0.82 mmol) and N — Hydroxy Cic acid imide (115 rag, 1. . ⁇ ) was dissolved in N, N-dimethylformamide (4 ml) and cooled to 4.
- N, N'-dicyclohexanol canebodiimide (206 nig, 1.0 mmol) was added, and the mixture was stirred at 4 for 2 hours.
- N "— T rt -G1y-Phe-Gly-Gly (1 1) (579 mg, 1.0 min ol) and N—hydro N, N'-dicyclohexane was added to a solution of succinic acid imide (127 mg, 1.1 mmol) in N, ⁇ -dimethylaminophenol (4 ml).
- Hexinorelation force Norepo diimide (226 mg, 1.1 mmol) was added, followed by DXR (544 mg, 1.0 mmol) of N, ⁇ -dimethylformaldehyde.
- N — T rt -G 1 y (15) (127 mg, 0,40 ranio 1) and N — hydroxysuccinic acid imine (51 mg, 0.44 mmo 1) solution of N, N-dimethyl honoleamide (4 Hi 1) in N, N'-dicyclohexane Hexinole force is added to the mixture (91 mg, 0.444 mmol), followed by the DXR (220 mg, 0.40 mmol).
- N T rt-G 1 y — G 1 y-G 1 y-G 1 y (1 9) (488 mg, 1.0 mo) ol) and N — Hydroxysuccinic acid imide (127 mg, 1.1 mmo 1) in N, N — Dimethyl honolem amide (5 ml) solution N, N'-dicyclohexanol canebodiimide (227 ing, 1.1 lmol) was added to the mixture, and then DXR (544 mg, 1.0 ramol) was added.
- the reaction solution was purified by using a dialysis membrane (molecular weight cutoff: 12,000-: L4,000, manufactured by Spectrum) and purified water as the external solution.
- the cation exchange resin AG50W-X8 (Na + type), BI0-RAD
- Dialysis was performed at 4 ° C for 2 minutes.
- the dialysate was removed and lyophilized to give the title compound (23) (1085 nig) .
- the ratio was 6.1% (% by weight) as calculated from the visible absorbance at 4778 nm and the total weight of the complex.
- the UV-visible absorption spectrum of this complex and the gel elution pattern (detection: visible absorbance at 478 nm) are shown in Figures 1 and 2, respectively. It is as follows.
- carboxymethyl pullulannatrium salt (6) 200 ng
- water N, N—dimethyl phenol Water of a mixture of mid (1: 1) (6 l) and 3'-N-Gly-DXR-HCl (16) (15 mg): NN—dimethyl methyl amide (1: 1) mixture (2 ml)
- NN dimethyl methyl amide (1: 1) mixture (2 ml)
- the drug introduction rate of this complex was 3.1% (% by weight) as calculated from the visible absorbance at 478 nm and the total weight force of the complex. .
- Example 2 The same method as in Example 1 was used except that (Spectram Co., Ltd.) was used, and the carboxymethyl phenol phenol salt (8)
- carboxymethylpurullan sodium salt (2) 200 mg in water: N, N-dimethylformamide (2) 1: 1) Water of the mixture (6 ml) and 3'-N- (Gly-Phe) -DNR ⁇ HC1 (18) (32 mg): N, N'-dimethyl Honolem Amide (1: 1) mixed solution (2 ml) and 11-Ethoxy canine 2-Jetoxy 1, 2-Dihydroquino
- the title compound (30) (185 rag) was obtained by reacting with phosphorus (200 mg).
- the drug incorporation rate of this conjugate was 5.6% (% by weight) as calculated from the visible absorbance at 4788 nm and the total weight of the conjugate.
- carboxysilyl methyl prunanna sodium salt (2) (3 OO mg) of water: N, N-dimethyl phenol beam ⁇ Mi de, (1: 1) mixture (9 ml) and 3 '- N - (G 1 y) 6 - DX R ⁇ HC 1 (3 6) water (6 6 mg): N, N - Dimethyl honole amide (1: 1) mixed solution (6 m1) and 1 x 1 x 1 x 2 x 1 x 1,2 x Reaction with loquinolin (300 mg) to give the title compound (39) (327 mg).
- the drug introduction rate of this complex is at 4788 nm. It was 6.3% (% by weight) as calculated from the visible absorbance and the total weight of the complex.
- carboxysilyl methyl prunannatrim salt (2) (250 mg) in water: N, N-dimethinol (1 : 1) mixed solution (7.5 ml) and 3'-N- (Phe-G1y) -DXRHC1 (3 8) (45 mg) water: N, N-Dimethyl honoleam amide (1: 1) mixture (2.5 ml) and 1-ethoxyquin
- the title compound (40) (223 mg) was obtained by reacting with 2-ethoxy-1,2 -dihydroxyquinoline (250 mg).
- the drug introduction rate of this complex was 6.5% (% by weight) as calculated from the visible absorbance at 4788 nm and the total weight of the complex.
- Purulan (1) (3.2 g, weight average molecular weight: about 150,000) (manufactured by Hayashibara Biochemical Laboratory Co., Ltd.) and lithium chloride (2.5 g) were added to N, N — Dissolved in dichloromethane (3 O ml). Next, succinic anhydride (3.0 g) and N-methyl phenol (3.03 g) were added, and the mixture was stirred at room temperature for 1 hour. After the reaction, methanol (100 ml) was added, and the mixture was centrifuged, and the deposited precipitate was dissolved in water (30 ml).
- Example 15 3'-N- (G1y-2Gly-Phe-Gly) -DXR (42) According to the same method as in Example 1.
- Succinyl pullulan sodium salt (41) (300 rag) with water: ,, ⁇ —dimethylformamide (1: 1) mixture (9 ml) 3'-N- (Gly-Gly-Phe-Gly) -DXR ⁇ HC1 (10) (66 mg) water: N, N—Dimethyl honolamide 1: 1) Mixture (3 ml) and 1-Ethoxycarbonyl 2-Ethoxy 1, 2-Dihydroquinoline
- lysozyme derived from egg white, 51,500 Units / mgso 1 id, manufactured by Seikagaku Corporation
- the reaction solution was 99.5% ethanol
- canolepoxmethylmethyltin sodium 600 mg was dissolved in a saturated sodium hydrogen carbonate solution (600 ml), and acetic anhydride was added. (2.4 ml) was added in four portions, followed by stirring at 4 overnight.
- the reaction solution was purified by using a dialysis membrane (molecular weight cut-off 12, 000 to 14, 000, manufactured by Spectrum) using purified water as the external solution. Dialysis was performed at 4 e C for 3 days.
- the reaction solution was passed through a membrane filter (0.22 ⁇ m), and this solution was added to 99.5% ethanol (600 ml) to form The precipitate was washed with 95% ethanol, acetone and ether in that order, and dried under reduced pressure to obtain the title compound (43) (550 mg).
- the molecular weight determined by the gel filtration method using dextran as a standard substance was about 70,000.o
- the drug introduction rate of this complex was 2.7% (% by weight) as calculated from the visible absorbance at 4788 nm and the total weight force of the complex. .
- the UV ⁇ visible absorption spectrum and gel filtration elution pattern (detection: visible absorbance at 478 nm) of this complex are shown in Figure 9 and Figure 10, respectively. It is as expected.
- Carboxymethyl dextran sodium salt (45) Dextran (molecular weight: about 70,000, product of PANOLEMASIA) (10 g) is added to 6 Dissolve in N-sodium hydroxide solution (8.3 ml) to give 70. Heated to C. Monochloroacetic acid (2.0 g) was added, and the mixture was stirred at 70 eC for 20 minutes. After the reaction solution was cooled on ice, acetic acid was added to adjust the pH to 5.5, and this solution was added to methanol (500 ml). The precipitate that produced the reaction solution was dissolved in purified water (20 ml), and the solution was dialyzed (molecular weight cutoff: 1200 to 14,000, manufactured by Spectra).
- the solution was dialyzed for 2 days at 4 eC using purified water as an external solution.
- the dialysate was collected and lyophilized to give the title compound (45) (0.9 g).
- the degree of carboxymethylation per saccharide residue of this substance was 0.6, as determined by the titration of anorecary.
- Ion-exchange resin (AG50W-X2 (H + type), BIO-RAD) Add to 60 ml of column, and elute the solution further with anion-exchange resin (AG1— X 2 (C 1 — type), BIO-RAD) was added to 6 O ml column. The final eluate was concentrated under reduced pressure to 250 ml and added to 99.5% ethanol (800 ml). The resulting precipitate is washed in the order of 95% ethanol, acetate, and ether, dried under reduced pressure, and dried to obtain a low-molecular-weight mannoglucan (6.02 g). Obtained.
- the low-molecular-weight mannoglucan (3.98 g) thus obtained was dissolved in a 1 M sodium chloride solution (400 ml), and then the methanol was added. (533 ml) was added. The resulting precipitate was dissolved in purified water (100, 1) and added to 99.5% ethanol (400 ml). The mixture was washed in the order of alcohol, acetate, and ether, and dried under reduced pressure to obtain low-molecular-weight mannoglucan (2.0 g).
- the drug introduction rate of this complex was 4.5% (% by weight), as calculated from the visible absorbance at 4788 nm and the total weight of the complex.
- O UV of the complex ⁇ Visible absorption spectrum and gel over-elution pattern (detection: visible absorbance at 478 ⁇ m) are shown in Fig. 13 respectively. , As shown in Figure 14
- N-acetyl de-N-sulfated heparin sodium salt (49) (340 mg) in water: N, N-dimethylamino-holonamide (1 : 1) Mixed solution (20 ml) and water of 3'-N- (G1y-Gly-Phe-Gly) -DXR ⁇ HC1 (10) (75mg): N, N — ⁇ ⁇ ⁇ ⁇ 1 (1 W 7
- this sodium hyaluronate salt (700 mg) was dissolved in a 0.1 M sodium chloride solution (70 ml), and the solution was prepared in advance.
- An anion-exchange resin (AGMP-1 (C1-type), BIO-RAD) equilibrated with 0.1 M sodium chloride solution was added to 70 ml of the column. Then, elution was carried out at various salt concentrations to obtain four fractions containing hyaluronic acid having a molecular weight corresponding to the salt concentration. Each of these eluates was added to 99.5% ethanol (1.5 liters), and the resulting precipitate was dissolved in distilled water (10 ml).
- the eluate was added to 99,5% ethanol (100 ml) by passing through a branfinolator (0.1%), and the resulting precipitate was added to 95% ethanol.
- sodium hyaluronate was added to (51) 255 mg, (52) 17 73 mg, 109 mg, 84 mg respectively. mg.
- the molecular weights determined by gel filtration using dextran as the standard were about 80,000, 170,000, 27,000 and 41,000, respectively.
- the title compound (53) (164 mg) was obtained by reacting with 150 mg of droquinoline.
- the drug introduction rate of this complex was 6.2%, as calculated from the visible absorbance at 4788 nm and the total weight of the complex.
- the ultraviolet and visible absorption spectra of this complex and the elution pattern of gel filtration are shown in Figs. 17 and 18, respectively. That's right.
- Example 20 Method similar to Example 20 except that sodium hyaluronate (52) was used instead of sodium hyaluronate (51) The title compound (54) (163 mg) was obtained.
- the drug introduction rate of this complex was 5.7%, as calculated from the visible absorbance at 4788 ⁇ m and the total weight of the complex.
- Hyaluronic acid sodium salt 3'-N- (G1y-G)
- a part of the reference example is shown below as a skim.
- the drug conjugate according to the present invention showed an excellent antitumor effect at any dose as compared to doxonorebicin.
- Example 5 The compound (27) obtained in Example 5 was used as a test compound using a female female rat (6 weeks old, 110 ⁇ 10 g) as a test compound.
- the obtained compound (23) or doxorubicin dissolved in physiological saline was administered into the tail vein of 10 mg / kg as 5 animals per group. Changes in body weight and survival after administration were examined and used as indicators of toxicity and side effects. After sample administration The change in weight of the rat was shown as a percentage of the weight at the time of sample administration.
- the weight change of the rats in the 10 mg / kg administration group is as shown in FIG.
- Doxonorubicin and the drug conjugate according to the present invention tended to lose weight slightly in the early stage after administration, but to a lesser extent than doxorubicin. It was. Furthermore, in the drug conjugate administration group, the body weight increased thereafter, and recovered to around 10 days after administration of the conjugate to the weight at the time of administration. On the other hand, in the doxorubicin group, there were deaths without recovery of body weight at the time of administration.
- the drug conjugate according to the present invention could be a useful high molecular drug with an improved therapeutic index.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/325,296 US5688931A (en) | 1993-02-26 | 1994-02-28 | Polysaccharide derivatives and drug carriers |
DK94907702T DK0640622T3 (da) | 1993-02-26 | 1994-02-28 | Polysaccharidderivat og lægemiddelbærer |
DE69425464T DE69425464T2 (de) | 1993-02-26 | 1994-02-28 | Polysaccharidderivat und wirkstoffträger |
AT94907702T ATE195324T1 (de) | 1993-02-26 | 1994-02-28 | Polysaccharidderivat und wirkstoffträger |
CA002134348A CA2134348C (en) | 1993-02-26 | 1994-02-28 | Polysaccharide derivatives and drug carriers |
EP94907702A EP0640622B1 (en) | 1993-02-26 | 1994-02-28 | Polysaccharide derivative and drug carrier |
GR20000402104T GR3034416T3 (en) | 1993-02-26 | 2000-09-18 | Polysaccharide derivative and drug carrier. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3863593 | 1993-02-26 | ||
JP5/38635 | 1993-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994019376A1 true WO1994019376A1 (en) | 1994-09-01 |
Family
ID=12530705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1994/000322 WO1994019376A1 (en) | 1993-02-26 | 1994-02-28 | Polysaccharide derivative and drug carrier |
Country Status (11)
Country | Link |
---|---|
US (1) | US5688931A (ja) |
EP (1) | EP0640622B1 (ja) |
JP (1) | JP2610792B2 (ja) |
AT (1) | ATE195324T1 (ja) |
CA (1) | CA2134348C (ja) |
DE (1) | DE69425464T2 (ja) |
DK (1) | DK0640622T3 (ja) |
ES (1) | ES2149867T3 (ja) |
GR (1) | GR3034416T3 (ja) |
PT (1) | PT640622E (ja) |
WO (1) | WO1994019376A1 (ja) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0757049A1 (en) | 1995-08-02 | 1997-02-05 | Tanabe Seiyaku Co., Ltd. | Camptothecin derivatives |
EP0781781A2 (en) | 1995-12-28 | 1997-07-02 | Tanabe Seiyaku Co., Ltd. | Camptothecin derivatives |
WO1999061061A1 (fr) * | 1998-05-22 | 1999-12-02 | Daiichi Pharmaceutical Co., Ltd. | Composites medicamenteux |
JP2001081103A (ja) * | 1999-09-13 | 2001-03-27 | Denki Kagaku Kogyo Kk | ヒアルロン酸結合薬剤 |
US6291671B1 (en) | 1996-06-06 | 2001-09-18 | Daiichi Pharmaceutical Co., Ltd. | Process for producing drug complexes |
US6436912B1 (en) | 1996-06-06 | 2002-08-20 | Daiichi Pharmaceutical Co., Ltd. | Drug complexes |
CN1133654C (zh) * | 1999-08-05 | 2004-01-07 | 武汉大学 | 灵芝α-(1→3)-D-葡聚糖羧甲基化衍生物及其用途和制备方法 |
US6811996B1 (en) | 1998-10-30 | 2004-11-02 | Daiichi Pharmaceutical Co., Ltd. | DDS compounds and method for assaying the same |
WO2005085294A1 (ja) | 2004-03-05 | 2005-09-15 | Denki Kagaku Kogyo Kabushiki Kaisha | ヒアルロン酸−メトトレキサート結合体 |
JP2006504747A (ja) * | 2002-10-18 | 2006-02-09 | フィディア ファルマチェウティチ ソシエタ ペル アチオニ | ヒアルロン酸又はヒアルロン酸誘導体に共有結合したタキサン類 |
JP2010516633A (ja) * | 2007-01-18 | 2010-05-20 | 天津和美生物技▲術▼有限公司 | 抗癌活性を有するテトラサイクリン・アントラキノン系化合物 |
US7807675B2 (en) | 2004-04-02 | 2010-10-05 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid-methotrexate conjugate |
US8143391B2 (en) | 2004-09-07 | 2012-03-27 | Chugai Seiyaku Kabushiki Kaisha | Process for producing water-soluble hyaluronic acid modification |
WO2016159159A1 (ja) * | 2015-03-31 | 2016-10-06 | キユーピー株式会社 | ヒアルロン酸誘導体およびその製造方法、ならびにヒアルロン酸誘導体を含む化粧料、食品組成物および医薬組成物 |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6017901A (en) * | 1995-05-10 | 2000-01-25 | Fidia Advanced Bioplymers S.R.L. | Heavy metal salts of succinic acid hemiesters with hyaluronic acid or hyaluronic acid esters, a process for their preparation and relative pharmaceutical compositions |
AU1671997A (en) * | 1996-02-13 | 1997-09-02 | Dainippon Pharmaceutical Co. Ltd. | Drug delivery system using galactoxyloglucan |
EP0895784B1 (en) * | 1996-04-15 | 2005-11-23 | Asahi Kasei Kabushiki Kaisha | Drug complexes comprising taxane compounds or steroids |
DE19640207A1 (de) * | 1996-09-30 | 1998-04-02 | Bayer Ag | Glycokonjugate von modifizierten Camptothecin-Derivaten (A- oder B-Ring-Verknüpfung) |
CA2267328A1 (en) * | 1996-09-30 | 1998-04-09 | Bayer Aktiengesellschaft | Glycoconjugates from modified camptothecin derivates (20-o-linkage) |
ID23424A (id) * | 1997-05-14 | 2000-04-20 | Bayer Ag | Glikokonjugat dari 20(s)-kamptotesin |
ES2245805T3 (es) * | 1997-10-03 | 2006-01-16 | Galenica Pharmaceuticals, Inc. | Polisacaridos que forman iminas, preparacion de los mismos y el uso de los mismos como adyuvantes de inmunoestimulantes. |
AU773420B2 (en) * | 1998-12-11 | 2004-05-27 | Medarex, Inc. | Prodrug compounds and process for preparation thereof |
US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
KR20030031502A (ko) * | 2000-06-29 | 2003-04-21 | 다이이찌 세이야꾸 가부시기가이샤 | 디디에스 화합물 및 그의 제조방법 |
TWI313609B (en) * | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
US20030092608A1 (en) * | 2001-08-21 | 2003-05-15 | Takayuki Kawaguchi | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
US7906102B2 (en) | 2001-10-03 | 2011-03-15 | Vanderbilt University | Ligands to radiation-induced molecules |
EP1572933A4 (en) | 2002-02-13 | 2007-09-05 | Univ Duke | MODULATION OF IMMUNE RESPONSE BY POLYPEPTIDES OF RESPONSE TO STRESS BINDING TO NON PEPTIDES |
GB2386899B (en) * | 2002-03-25 | 2005-10-26 | Johnson & Johnson Medical Ltd | Wound dressings comprising chemically modified polysaccharides |
CN101721697A (zh) * | 2002-10-01 | 2010-06-09 | 诺华疫苗和诊断公司 | 抗癌及抗感染性疾病组合物及其使用方法 |
CN101184780B (zh) | 2005-05-05 | 2012-10-03 | 森馨香料公司 | β-葡聚糖和甘露聚糖的制备 |
ITPD20050242A1 (it) | 2005-08-03 | 2007-02-04 | Fidia Farmaceutici | Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico |
FR2914305B1 (fr) * | 2007-03-29 | 2009-07-03 | Proteins & Peptides Man | Dextran fonctionnalise par des amino-acides hydrophobes. |
US20120041079A1 (en) * | 2006-09-26 | 2012-02-16 | Adocia | Dextran functionalized by hydrophobic amino acids |
CN1973902B (zh) * | 2006-12-12 | 2010-11-10 | 东北师范大学 | 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法 |
US20090163936A1 (en) * | 2007-12-21 | 2009-06-25 | Chunlin Yang | Coated Tissue Engineering Scaffold |
US20110200525A1 (en) * | 2008-10-09 | 2011-08-18 | Patz Jr Edward F | Vhh antibody fragments for use in the detection and treatment of cancer |
US8685458B2 (en) | 2009-03-05 | 2014-04-01 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives |
US8518405B2 (en) | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
WO2011060250A1 (en) * | 2009-11-13 | 2011-05-19 | Bend Research, Inc. | Cationic dextran polymer derivatives |
US8815294B2 (en) | 2010-09-03 | 2014-08-26 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives and a carrier material |
EA201390874A1 (ru) | 2010-12-14 | 2013-12-30 | Нэшнл Юниверсити Оф Сингапур | Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение |
US9060938B2 (en) | 2011-05-10 | 2015-06-23 | Bend Research, Inc. | Pharmaceutical compositions of active agents and cationic dextran polymer derivatives |
US11135316B2 (en) | 2014-01-31 | 2021-10-05 | Washington University | Imaging and treatment of pathophysiologic conditions by Cerenkov radiation |
US9974870B2 (en) | 2014-06-09 | 2018-05-22 | Washington University | Compositions and methods for treatment and imaging using nanoparticles |
ES2830392T3 (es) | 2014-07-23 | 2021-06-03 | Ohio State Innovation Foundation | Métodos y composiciones relacionados con fragmentos de anticuerpo que se unen a la glicoproteína 72 asociada a tumores (TAG-72) |
US10449261B2 (en) | 2014-07-24 | 2019-10-22 | Washington University | Compositions targeting radiation-induced molecules and methods of use thereof |
US11788091B2 (en) | 2019-08-21 | 2023-10-17 | University Of Virginia Patent Foundation | Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59220197A (ja) * | 1983-05-30 | 1984-12-11 | Snow Brand Milk Prod Co Ltd | 新規な含窒素多糖体およびその製造方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2517760B2 (ja) * | 1989-05-11 | 1996-07-24 | 新技術事業団 | 水溶性高分子化医薬製剤 |
ATE152455T1 (de) * | 1990-08-17 | 1997-05-15 | Drug Delivery System Inst Ltd | N-acetylcarboxymethylchitosanderivat und verfahren zur herstellung |
CA2070672C (en) * | 1990-10-18 | 2002-10-08 | Kazuo Akima | Compound of medicinal ingredient and hyaluronic acid and process for producing the same |
ATE166361T1 (de) * | 1991-02-21 | 1998-06-15 | Drug Delivery System Inst Ltd | Carboxymethylmannoglukan und derivate davon |
-
1994
- 1994-02-28 PT PT94907702T patent/PT640622E/pt unknown
- 1994-02-28 ES ES94907702T patent/ES2149867T3/es not_active Expired - Lifetime
- 1994-02-28 DK DK94907702T patent/DK0640622T3/da active
- 1994-02-28 WO PCT/JP1994/000322 patent/WO1994019376A1/ja active IP Right Grant
- 1994-02-28 AT AT94907702T patent/ATE195324T1/de not_active IP Right Cessation
- 1994-02-28 EP EP94907702A patent/EP0640622B1/en not_active Expired - Lifetime
- 1994-02-28 CA CA002134348A patent/CA2134348C/en not_active Expired - Fee Related
- 1994-02-28 JP JP6515876A patent/JP2610792B2/ja not_active Expired - Fee Related
- 1994-02-28 DE DE69425464T patent/DE69425464T2/de not_active Expired - Lifetime
- 1994-02-28 US US08/325,296 patent/US5688931A/en not_active Expired - Lifetime
-
2000
- 2000-09-18 GR GR20000402104T patent/GR3034416T3/el not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59220197A (ja) * | 1983-05-30 | 1984-12-11 | Snow Brand Milk Prod Co Ltd | 新規な含窒素多糖体およびその製造方法 |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0757049A1 (en) | 1995-08-02 | 1997-02-05 | Tanabe Seiyaku Co., Ltd. | Camptothecin derivatives |
EP0781781A2 (en) | 1995-12-28 | 1997-07-02 | Tanabe Seiyaku Co., Ltd. | Camptothecin derivatives |
EP0781781A3 (en) * | 1995-12-28 | 1998-04-01 | Tanabe Seiyaku Co., Ltd. | Camptothecin derivatives |
US6291671B1 (en) | 1996-06-06 | 2001-09-18 | Daiichi Pharmaceutical Co., Ltd. | Process for producing drug complexes |
US6436912B1 (en) | 1996-06-06 | 2002-08-20 | Daiichi Pharmaceutical Co., Ltd. | Drug complexes |
US6838450B2 (en) | 1996-06-06 | 2005-01-04 | Daiichi Pharmaceutical Co., Ltd | Drug complex |
US6835807B1 (en) | 1998-05-22 | 2004-12-28 | Daiichi Pharmaceuticals Co., Ltd. | Drug complex and drug delivery system |
WO1999061061A1 (fr) * | 1998-05-22 | 1999-12-02 | Daiichi Pharmaceutical Co., Ltd. | Composites medicamenteux |
JP4560210B2 (ja) * | 1998-05-22 | 2010-10-13 | 第一三共株式会社 | 薬物複合体 |
EA003398B1 (ru) * | 1998-05-22 | 2003-04-24 | Дайити Фармасьютикал Ко., Лтд. | Лекарственный комплекс c полимерным носителем |
US7041818B2 (en) | 1998-10-30 | 2006-05-09 | Daiichi Pharmaceutical Co., Ltd. | DDS compound and method for measurement thereof |
US6811996B1 (en) | 1998-10-30 | 2004-11-02 | Daiichi Pharmaceutical Co., Ltd. | DDS compounds and method for assaying the same |
CN1133654C (zh) * | 1999-08-05 | 2004-01-07 | 武汉大学 | 灵芝α-(1→3)-D-葡聚糖羧甲基化衍生物及其用途和制备方法 |
JP2001081103A (ja) * | 1999-09-13 | 2001-03-27 | Denki Kagaku Kogyo Kk | ヒアルロン酸結合薬剤 |
JP4704753B2 (ja) * | 2002-10-18 | 2011-06-22 | フィディア ファルマチェウティチ ソシエタ ペル アチオニ | ヒアルロン酸又はヒアルロン酸誘導体に共有結合したタキサン類 |
JP2006504747A (ja) * | 2002-10-18 | 2006-02-09 | フィディア ファルマチェウティチ ソシエタ ペル アチオニ | ヒアルロン酸又はヒアルロン酸誘導体に共有結合したタキサン類 |
WO2005085294A1 (ja) | 2004-03-05 | 2005-09-15 | Denki Kagaku Kogyo Kabushiki Kaisha | ヒアルロン酸−メトトレキサート結合体 |
AU2005219733B2 (en) * | 2004-03-05 | 2010-05-06 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid-methotrexate conjugate |
JP4927536B2 (ja) * | 2004-03-05 | 2012-05-09 | 電気化学工業株式会社 | ヒアルロン酸−メトトレキサート結合体 |
JPWO2005085294A1 (ja) * | 2004-03-05 | 2007-12-13 | 電気化学工業株式会社 | ヒアルロン酸−メトトレキサート結合体 |
EP1724287A4 (en) * | 2004-03-05 | 2010-10-27 | Denki Kagaku Kogyo Kk | HYALURONIC / METHOTREXATE CONNECTION |
US8088916B2 (en) | 2004-03-05 | 2012-01-03 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid-methotrexate conjugate |
AU2005219733C1 (en) * | 2004-03-05 | 2010-12-16 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid-methotrexate conjugate |
US7807675B2 (en) | 2004-04-02 | 2010-10-05 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid-methotrexate conjugate |
EP1739097A4 (en) * | 2004-04-02 | 2010-12-08 | Denki Kagaku Kogyo Kk | HYALURONIC ACID / METHOTREXATE COMPOUND |
US8143391B2 (en) | 2004-09-07 | 2012-03-27 | Chugai Seiyaku Kabushiki Kaisha | Process for producing water-soluble hyaluronic acid modification |
US9394379B2 (en) | 2004-09-07 | 2016-07-19 | Chugai Seiyaku Kabushiki Kaisha | Process for producing water-soluble hyaluronic acid modification |
JP2010516633A (ja) * | 2007-01-18 | 2010-05-20 | 天津和美生物技▲術▼有限公司 | 抗癌活性を有するテトラサイクリン・アントラキノン系化合物 |
WO2016159159A1 (ja) * | 2015-03-31 | 2016-10-06 | キユーピー株式会社 | ヒアルロン酸誘導体およびその製造方法、ならびにヒアルロン酸誘導体を含む化粧料、食品組成物および医薬組成物 |
JPWO2016159159A1 (ja) * | 2015-03-31 | 2018-01-25 | キユーピー株式会社 | ヒアルロン酸誘導体およびその製造方法、ならびにヒアルロン酸誘導体を含む化粧料、食品組成物および医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
ES2149867T3 (es) | 2000-11-16 |
US5688931A (en) | 1997-11-18 |
GR3034416T3 (en) | 2000-12-29 |
PT640622E (pt) | 2000-11-30 |
CA2134348A1 (en) | 1994-08-27 |
ATE195324T1 (de) | 2000-08-15 |
JP2610792B2 (ja) | 1997-05-14 |
EP0640622A1 (en) | 1995-03-01 |
EP0640622B1 (en) | 2000-08-09 |
DK0640622T3 (da) | 2000-10-23 |
DE69425464T2 (de) | 2001-05-23 |
CA2134348C (en) | 2007-01-02 |
DE69425464D1 (de) | 2000-09-14 |
EP0640622A4 (en) | 1996-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994019376A1 (en) | Polysaccharide derivative and drug carrier | |
US8318696B2 (en) | Polysaccharides with antithrombotic activity comprising at least one covalent bond with biotin or a biotin derivative | |
ES2245805T3 (es) | Polisacaridos que forman iminas, preparacion de los mismos y el uso de los mismos como adyuvantes de inmunoestimulantes. | |
DE69730352T2 (de) | Verfahren zur herstellung eines arzneimittelkomplexes | |
US7041818B2 (en) | DDS compound and method for measurement thereof | |
US5672334A (en) | Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans | |
Fujita et al. | Therapeutic effects of superoxide dismutase derivatives modified with mono-or polysaccharides on hepatic injury induced by ischemia/reperfusion | |
US5463022A (en) | N-acetylcarboxymethylchitosan derivatives and process for preparation thereof | |
JP3048198B2 (ja) | 硫酸化グリコサミノグリカノイド誘導体 | |
JP2604930B2 (ja) | ヒアルロン酸およびコンドロイチン誘導体 | |
JPH07508727A (ja) | 生体分子と結合したポリオキシメチレン−オキシエチレン共重合体 | |
KR20000016558A (ko) | 약물복합체 | |
JPH01503548A (ja) | ヘパリン誘導体 | |
US8492352B2 (en) | Polysaccharides with antithrombotic activity, including a covalent bond and an amino chain | |
CN101039963B (zh) | 生物素化十六糖,它们的制备方法及其用途 | |
KR101788536B1 (ko) | 상어유사 콘드로이틴 설페이트 및 이의 제조방법 | |
BE882541A (fr) | Nouvelles formes pharmaceutiques leur preparation et les compositions qui les contiennent | |
US20090239822A1 (en) | Process for the preparation of esters of diacerein with hyaluronic acid and pharmaceutical compositions containing such esters | |
USUI et al. | Preparation and antitumor activities of mitomycin C β-(1→ 6)-branched (1→ 3)-β-D-glucan conjugate | |
KR100481434B1 (ko) | 약물복합체의제조방법 | |
Koesoemowidodo et al. | A study on synthesis of Maleylated-chitosan to enhance chitosan solubility in water | |
JP2997848B2 (ja) | N―アセチルキトオリゴ糖とマイトマイシン類の複合体及び抗腫瘍剤 | |
JPH01301702A (ja) | 修飾ヘパリンおよび製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2134348 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994907702 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08325296 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1994907702 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994907702 Country of ref document: EP |